HLA-DRA and neoplasm: Although the level of HIST2H2AA3, rather than that of LUZP6 and HLA-DRA, in tumor tissues was positively associated with KRAS mutation, there was no significant difference in the level of HIST2H2AA3, LUZP6 or HLA-DRA expression across the disease stages.